PuSH - Publication Server of Helmholtz Zentrum München

Lipidomic approach for stratification of acute myeloid leukemia patients.

PLoS ONE 12:e0168781 (2017)
Publishers Version Research data DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
as soon as is submitted to ZB.
The pathogenesis and progression of many tumors, including hematologic malignancies is highly dependent on enhanced lipogenesis. De novo fatty-acid synthesis permits accelerated proliferation of tumor cells by providing membrane components but these may also alter physicochemical properties of lipid bilayers, which can impact signaling or even increase drug resistance in cancer cells. Cancer type-specific lipid profiles would permit us to monitor and interpret actual effects of lipid changes, potential fingerprints of individual tumors to be explored as diagnostic markers. We have used the shotgun MS approach to identify lipid patterns in different types of acute myeloid leukemia (AML) patients that either show no karyotype change or belong to t(8; 21) or inv 16 types. Differences in lipidomes of t(8; 21) and inv(16) patients, as compared to AML patients without karyotype change, presented mostly as substantial modulation of ceramide/sphingolipid synthesis. Furthermore, between the t(8; 21) and all other patients we observed significant changes in physicochemical membrane properties. These were related to a marked alteration in lipid saturation levels. The discovered differences in lipid profiles of various AML types improve our understanding of the pathobiochemical pathways involved and may serve in the development of diagnostic tools.
Altmetric
Additional Metrics?
Edit extra informations Login
Publication type Article: Journal article
Document type Scientific Article
Keywords Fatty-acid Synthase; Throughput Shotgun Lipidomics; Acute Myelogenous Leukemia; Mass-spectrometry; Breast-cancer; Glucosylceramide Synthase; Sphingolipid Metabolism; Multidrug-resistance; Cell-proliferation; Signaling Pathways
Reviewing status
Institute(s) Institute for Pancreatic Beta Cell Research (IPI)